---
title: "BEONE MEDICINES 1H Net Profit Swells 386% to USD464M; Full-year Revenue and Earnings Guidance Raised; US Premarket Up ~4%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/294951739.md"
description: "BeOne Medicines reported a 386% surge in H1 net profit to USD464M and raised full-year revenue guidance to USD6.6-6.8B. The company also increased operating profit forecasts. Shares rose ~4% in US premarket trading following the announcement of strong interim results."
datetime: "2026-08-05T10:46:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/294951739.md)
  - [en](https://longbridge.com/en/news/294951739.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/294951739.md)
generator: "portal-rs"
---

# BEONE MEDICINES 1H Net Profit Swells 386% to USD464M; Full-year Revenue and Earnings Guidance Raised; US Premarket Up ~4%

BEONE MEDICINES (06160.HK) +5.100 (+2.634%) Short selling $255.71M; Ratio 28.958% announced its interim results for the six months ended June 2026. Total revenue amounted to USD3.219 billion, up 32.3% YoY. Net profit spiked 386% YoY to USD464 million. EPS was USD0.32, while EPS per ADS was USD4.17. Non-GAAP adjusted net profit for 1H reached USD819.5 million, up about 1.1x YoY. Non-GAAP adjusted EPS was USD0.57. Non-GAAP adjusted EPS per ADS was USD7.37.  

The company updated its full-year guidance and raised total revenue guidance to between USD6.6 billion and USD6.8 billion, from the previous USD6.3 billion to USD6.5 billion. GAAP gross margin guidance was maintained at the high end of the 80% range. GAAP operating profit guidance was raised to between USD1 billion and USD1.1 billion, from the previous USD750 million to USD850 million.

BeOne Medicines Ltd. (ONC.US) leaped 3.9% in US premarket trading to USD355.49.  
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-08-05 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AASTOCKS Financial News

### Related Stocks

- [BGNE.US](https://longbridge.com/en/quote/BGNE.US.md)
- [ONC.US](https://longbridge.com/en/quote/ONC.US.md)
- [06160.HK](https://longbridge.com/en/quote/06160.HK.md)
- [688235.CN](https://longbridge.com/en/quote/688235.CN.md)

## Related News & Research

- [BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines | ONC Stock News](https://longbridge.com/en/news/297552849.md)
- [How Investors Are Reacting To BeOne Medicines (ONC) First-Line HER2-Positive GEA Immunotherapy Approval](https://longbridge.com/en/news/297146976.md)
- [BeOne Medicines to Present at the Morgan Stanley Annual Global Healthcare Conference | ONC Stock News](https://longbridge.com/en/news/297636674.md)
- [BUZZ-Mid-cap drugmakers face limited impact from Trump drug pricing deals, analysts say](https://longbridge.com/en/news/297637201.md)
- [BeOne says FDA approves Tevimbra-based first-line regimen for HER2+ gastroesophageal cancer](https://longbridge.com/en/news/296930925.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**